Popular on s4story
- Detroit Disrupter Judge Leonia Lloyd Wields a 'Diamond Gavel' for Change - 142
- Author Tammy Sollenberger Joins Multi-Author Event at The Country Bookseller - 103
- Be Taylor Productions Partners With Walmart's Online Store, To Release New Comic Book Nationwide
- Ever thought about adopting? Critical information from industry insiders, adult adoptees and international experts. Save up to $60,000 in hidden fees
- Terrorism is again on the rise warnings in new TERROR STRIKES book release
- Mariam Sheriff Releases Her Debut Novel - The Deep: A Tale Beyond The Waves
- Risk Management Book Wins International Book Award
- Modern Treatise To Undergo A Gradual Rebrand
- Debut Novel by Robert Stewart, No Greater Duty - Available NOW!
- PropTech 2022: Most Active Investors and Top Startups Released at F50 Global Capital Summit
Similar on s4story
- 65% of Today's Workforce Is Actively Looking for Another Job; Culture Over Everything Is the Solution
- Signs By Veterans and Savage Shakers Founder Announces Sponsorship for #TEAMUSA Para-Athlete Brian Conwell
- James Postrasija, CEO of Order Food Online on Platform Features/Benefits
- EPA's Renewable Fuel Standard Pathways Expand to Include Greasezilla® Advanced Biofuel as RIN-Qualified Feedstock
- Kano Laboratories, Makers of Kroil, Announces Refreshed Branding for Extended Line of Industrial Product Solutions
- Prolific Author Tam R. Luc Celebrates Positive Title IX Achievements and Pushes Businesswomen to the Next Level with Boss Up Summit
- Ismail Sirdah' Guide To Landing Event Sponsorships
- iTech offers 60-days free trial on expEDIum Medical Billing® product
- The Data Economics Company announces partnership with Incradia to release the ReVerse franchise on Lydion-based Game Development Platform
- Completion of funding round brings Metaphysiks one step closer to embodying the Metaverse
Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
S For Story/10543570
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck's HPV/Gardasil Franchise. Ms. Murphy joined Oragenics' Board of Directors in 2020.
"As a Board Member, Ms. Murphy's extensive experience in the vaccine industry has provided valuable insight for Oragenics' corporate and development strategies. Her proven leadership and execution will continue to elevate the potential of the Company and our pipeline programs," commented Fred Telling, Chairman of Board of Directors. "We are excited to have her strategic vision further implemented serving as President and Chief Executive Officer."
"I am honored to be appointed as the President and Chief Executive Officer and excited to create additional meaningful impact to accelerate growth and lead our team," said Kimberly Murphy, CEO. "I look forward to cultivating our strategic business and development objectives and creating value for our stakeholders opportunistically."
Most recently Ms. Murphy served as Vice President of the Influenza Franchise and Global Vaccine Commercialization Leader at GSK, with responsibility for the global influenza vaccines business and also served as Vice President and Global Marketing Head for GSK's shingles vaccine, SHINGRIX. Earlier Ms. Murphy was Vice President and Lead for the North America Vaccines Integration Planning Team where she integrated GSK's acquisition of Novartis AG's vaccine division and served as Vice President of U.S. Vaccines Customer Strategy and as Senior Director of U.S. Influenza Portfolio Strategy. She also had distinguished vaccine leadership careers at Merck & Co., Inc. and Novartis.
More on S For Story
Ms. Murphy currently serves as a Director of Blue Water Vaccines, Inc. (NASDAQ: BWV) and as Chairperson of Clarus Therapeutics Holdings Inc. (NASDAQ: CRXT). She previously served in Board and advisory roles for a privately held vaccine development company, the Biotechnology Industry Organization, the Biodefense Advisory Council and the Saint Joseph's University Pharmaceutical & Healthcare Marketing MBA Program.
Ms. Murphy holds a BA from Old Dominion University and an MBA from Saint Joseph's University, and completed the Marketing Excellence Program at the Wharton School of the University of Pennsylvania.
About Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the National Institutes of Health (NIH) and the National Research Council of Canada (NRC) with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information about Oragenics, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, the following: the Company's ability to advance the development of its vaccine candidate and lantibiotics candidate under the timelines and in accord with the milestones it projects; the Company's ability to obtain funding, non-dilutive or otherwise, for the development of the vaccine and lantibiotic product candidates, whether through its own cash on hand, or another alternative source; the regulatory application process, research and development stages, and future clinical data and analysis relating to vaccines and lantibiotics, including any meetings, decisions by regulatory authorities, such as the FDA and investigational review boards, whether favorable or unfavorable; the potential application of our vaccine candidate to variants and other coronaviruses; the Company's ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the nature of competition and development relating to COVID-19 immunization and therapeutic treatments and demand for vaccines and antibiotics; the Company's expectations as to administration, manufacturing, storage and distribution; other potential adverse impacts due to the global COVID-19 pandemic, such as delays in regulatory review, interruptions to manufacturers and supply chains, adverse impacts on healthcare systems and disruption of the global economy; and general economic and market conditions and risks, as well as other uncertainties described in our filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
More on S For Story
Contacts
Oragenics, Inc.
Michael Sullivan, Chief Financial Officer
813-286-7900
msullivan@oragenics.com
LHA Investor Relations
Tirth T. Patel
212-201-6614
tpatel@lhai.com
"As a Board Member, Ms. Murphy's extensive experience in the vaccine industry has provided valuable insight for Oragenics' corporate and development strategies. Her proven leadership and execution will continue to elevate the potential of the Company and our pipeline programs," commented Fred Telling, Chairman of Board of Directors. "We are excited to have her strategic vision further implemented serving as President and Chief Executive Officer."
"I am honored to be appointed as the President and Chief Executive Officer and excited to create additional meaningful impact to accelerate growth and lead our team," said Kimberly Murphy, CEO. "I look forward to cultivating our strategic business and development objectives and creating value for our stakeholders opportunistically."
Most recently Ms. Murphy served as Vice President of the Influenza Franchise and Global Vaccine Commercialization Leader at GSK, with responsibility for the global influenza vaccines business and also served as Vice President and Global Marketing Head for GSK's shingles vaccine, SHINGRIX. Earlier Ms. Murphy was Vice President and Lead for the North America Vaccines Integration Planning Team where she integrated GSK's acquisition of Novartis AG's vaccine division and served as Vice President of U.S. Vaccines Customer Strategy and as Senior Director of U.S. Influenza Portfolio Strategy. She also had distinguished vaccine leadership careers at Merck & Co., Inc. and Novartis.
More on S For Story
- James Postrasija, CEO of Order Food Online on Platform Features/Benefits
- Disney Good Neighbor Hotel Lulu is Open for the Summer
- International Bestselling Author Jaden Rae Publishes Journal Focused on Microdosing for Depression
- EPA's Renewable Fuel Standard Pathways Expand to Include Greasezilla® Advanced Biofuel as RIN-Qualified Feedstock
- Aspiring To Excellence Continues at Globe Star with CARF Accreditation
Ms. Murphy currently serves as a Director of Blue Water Vaccines, Inc. (NASDAQ: BWV) and as Chairperson of Clarus Therapeutics Holdings Inc. (NASDAQ: CRXT). She previously served in Board and advisory roles for a privately held vaccine development company, the Biotechnology Industry Organization, the Biodefense Advisory Council and the Saint Joseph's University Pharmaceutical & Healthcare Marketing MBA Program.
Ms. Murphy holds a BA from Old Dominion University and an MBA from Saint Joseph's University, and completed the Marketing Excellence Program at the Wharton School of the University of Pennsylvania.
About Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the National Institutes of Health (NIH) and the National Research Council of Canada (NRC) with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information about Oragenics, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, the following: the Company's ability to advance the development of its vaccine candidate and lantibiotics candidate under the timelines and in accord with the milestones it projects; the Company's ability to obtain funding, non-dilutive or otherwise, for the development of the vaccine and lantibiotic product candidates, whether through its own cash on hand, or another alternative source; the regulatory application process, research and development stages, and future clinical data and analysis relating to vaccines and lantibiotics, including any meetings, decisions by regulatory authorities, such as the FDA and investigational review boards, whether favorable or unfavorable; the potential application of our vaccine candidate to variants and other coronaviruses; the Company's ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the nature of competition and development relating to COVID-19 immunization and therapeutic treatments and demand for vaccines and antibiotics; the Company's expectations as to administration, manufacturing, storage and distribution; other potential adverse impacts due to the global COVID-19 pandemic, such as delays in regulatory review, interruptions to manufacturers and supply chains, adverse impacts on healthcare systems and disruption of the global economy; and general economic and market conditions and risks, as well as other uncertainties described in our filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
More on S For Story
- JKS Financial Sponsors Program To Teach High School Students Investment Skills
- Explosive New Book Debunks America's Crime Scare
- Don Barnhart's "Unapologetically Funny" Comedy Tour Keeps Las Vegas Laughing With 50% Discount
- Craig W Brearley Architecture Transitions to New Ownership While Maintaining a Tradition of Architec
- Moms of Addicted Loved Ones Find Hope
Contacts
Oragenics, Inc.
Michael Sullivan, Chief Financial Officer
813-286-7900
msullivan@oragenics.com
LHA Investor Relations
Tirth T. Patel
212-201-6614
tpatel@lhai.com
Filed Under: Business
0 Comments
Latest on S For Story
- Kindle FREE June 28-29: Powerful new memoir from Santa Molina-Marshall poised to help heal abuse victims through inspiring storytelling
- BOOK RELEASE | The Nurtured Mind: Wellness Workbook
- GoodLoan.io announces new program to unlock up to $500,000 for Home Equity Investment
- It's Time To Share Your Story!
- Beck Properties Group Hires Professional Marketing Team
- Cosplay Universe" Documentary to Premiere at Anime Expo & in Theaters this Summer
- Everything Will Be Okay: A Domestic Violence Survivor Finds Her Voice
- Kano Laboratories, Makers of Kroil, Announces Refreshed Branding for Extended Line of Industrial Product Solutions
- Fathym announces the addition of Sergio Sotolongo to its board of directors
- Prolific Author Tam R. Luc Celebrates Positive Title IX Achievements and Pushes Businesswomen to the Next Level with Boss Up Summit
- Avion Medical Skin Centres to offer innovative treatment for non-melanoma skin cancer patients
- Launch of Def Leppard beauty collection creating Hysteria in the makeup industry
- Courageous Women Throughout History
- Author celebrates 12 months and 6 books in DCI Steve Burt crime fiction series with book donations
- Pastor Tells the Story of His Parents' Religious Journey
- Ismail Sirdah' Guide To Landing Event Sponsorships
- Dalia Dupris Announces the Release of Anything But Love
- Children's Shoe Brand joins Soles4Souls in Ukrainian Refugee Relief Efforts
- iTech offers 60-days free trial on expEDIum Medical Billing® product
- The Data Economics Company announces partnership with Incradia to release the ReVerse franchise on Lydion-based Game Development Platform